Symbolbild · KI-generiert
BioMark Diagnostics Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
BioMark is a Canadian based company that is developing its advanced stage cancer diagnostic business. BioMark’s cancer diagnostics technology platform leverages "Omics" and machine learning which allows for early cancer detection. BioMark is currently focused on bringing its cancer diagnostic kits and detection solution to commercialization standards and hopes to commence distribution once clinical trials are complete and regulatory acceptance is obtained. For more information please visit the company’s website at www.biomarkdiagnostics.com
Company description as published by the issuer via Canadian Securities Exchange.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| BioMark Diagnostics Inc. | BUX | CSE | 43 Mio. USD |
| Ocumetics Technology Corp. | OTC | TSXV | 43 Mio. USD |
| Covalon Technologies Ltd. | COV | TSXV | 44 Mio. USD |
| Noveris Health Sciences Inc. | NVRS | CSE | 44 Mio. USD |
| Arch Biopartners Inc. | ARCH | TSXV | 39 Mio. USD |
| Planet 13 Holdings Inc. | PLTH | CSE | 38 Mio. USD |
| Eastwood Bio-Medical Canada Inc. | EBM | TSXV | 48 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.